Insider Trading disclosures for National Health Investors, Inc.

The latest disclosure was made by Candice W. Todd in National Health Investors, Inc. where a trade of 10,000 Stock Option (Right to Buy) 2025 done was reported to US exchanges on March 3, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Candice W. Todd	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
Charlotte A. Swafford	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
James R. Jobe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
Robert A. Mccabe	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
Tracy M.J. Colden	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
D. Eric Mendelson	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	25,000	25,000	-		-	Stock Option (Right to Buy) 2025
D. Eric Mendelson	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	25,000	25,000	-		-	Stock Option (Right to Buy) 2025
D. Eric Mendelson	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	25,000	25,000	-		-	Stock Option (Right to Buy) 2025
D. Eric Mendelson	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	8,000	96,527 (0%)	0%		0	Common Stock
Robert G. Adams	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	10,000	10,000	-		-	Stock Option (Right to Buy) 2025
Kristin S. Gaines	SVP/Chief Transaction Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	4,000	61,944 (0%)	0%		0	Common Stock
Kristin S. Gaines	SVP/Chief Transaction Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	8,333	8,333	-		-	Stock Option (Right to Buy) 2025
John L. Spaid	CFO/EVP Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
Kristin S. Gaines	SVP/Chief Transaction Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	8,333	8,333	-		-	Stock Option (Right to Buy) 2025
John L. Spaid	CFO/EVP Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
John L. Spaid	CFO/EVP Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	6,500	44,682 (0%)	0%		0	Common Stock
John L. Spaid	CFO/EVP Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
Kevin Carlton Pascoe	Chief Investment Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	5,500	61,330 (0%)	0%		0	Common Stock
Kevin Carlton Pascoe	Chief Investment Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
Kevin Carlton Pascoe	Chief Investment Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
Kevin Carlton Pascoe	Chief Investment Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	15,000	15,000	-		-	Stock Option (Right to Buy) 2025
Kristin S. Gaines	SVP/Chief Transaction Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Mar 2025	8,334	8,334	-		-	Stock Option (Right to Buy) 2025
John L. Spaid	CFO/EVP Finance	Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.96 per share.	23 Feb 2025	267	38,182 (0%)	0%	69.0	18,412	Common Stock
D. Eric Mendelson	Director, CEO and President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.96 per share.	23 Feb 2025	267	88,527 (0%)	0%	69.0	18,412	Common Stock
W. Andrew Adams	Director	Other type of transaction at price $ 0.00 per share.	27 Sep 2024	12,635	0 (0%)	0%		0	Common Stock by JMA Grandchildrens Trust
Kristin S. Gaines	SVP/Chief Transaction Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.66 per share.	25 Sep 2024	48,665	57,944 (0%)	0%	84.7	4,119,979	Common Stock
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share.	25 Sep 2024	18,333	69,942 (0%)	0%	69.2	1,268,644	Common Stock
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	25 Sep 2024	18,334	0	-		-	Stock Options (Right to Buy) 2-25-2021
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	25 Sep 2024	18,333	0	-		-	Stock Options (Right to Buy) 2-25-2021
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	25 Sep 2024	18,333	0	-		-	Stock Options (Right to Buy) 2-25-2021
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share.	25 Sep 2024	18,334	106,609 (0%)	0%	69.2	1,268,713	Common Stock
Kristin S. Gaines	SVP/Chief Transaction Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share.	25 Sep 2024	18,333	88,275 (0%)	0%	69.2	1,268,644	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	13,333	0	-		-	Stock Option (Right to Buy) 2023
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share.	05 Sep 2024	41,666	135,921 (0%)	0%	53.4	2,225,381	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share.	05 Sep 2024	41,666	177,587 (0%)	0%	53.4	2,225,381	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share.	05 Sep 2024	41,668	219,255 (0%)	0%	53.4	2,225,488	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share.	05 Sep 2024	13,333	67,589 (0%)	0%	54.7	729,715	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share.	05 Sep 2024	13,333	80,922 (0%)	0%	54.7	729,715	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share.	05 Sep 2024	13,333	94,255 (0%)	0%	57.8	770,114	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.10 per share.	05 Sep 2024	130,461	88,794 (0%)	0%	82.1	10,710,848	Common Stock
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	41,668	0	-		-	Stock Option (Right to buy) 2022
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	41,666	0	-		-	Stock Option (Right to buy) 2022
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	41,666	0	-		-	Stock Option (Right to buy) 2022
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	13,333	0	-		-	Stock Option (Right to Buy) 2023
D. Eric Mendelsohn	Director, CEO and President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	05 Sep 2024	13,333	0	-		-	Stock Option (Right to Buy) 2024
John L. Spaid	CFO/EVP Finance	Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share.	03 Sep 2024	8,500	88,086 (0%)	0%	57.8	490,960	Common Stock
John L. Spaid	CFO/EVP Finance	Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.43 per share.	03 Sep 2024	49,637	38,449 (0%)	0%	81.4	4,041,941	Common Stock
John L. Spaid	CFO/EVP Finance	Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share.	03 Sep 2024	8,500	79,586 (0%)	0%	54.7	465,205	Common Stock
John L. Spaid	CFO/EVP Finance	Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share.	03 Sep 2024	8,500	71,086 (0%)	0%	54.7	465,205	Common Stock
John L. Spaid	CFO/EVP Finance	Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.00 per share.	03 Sep 2024	1	62,586 (0%)	0%	53	53	Common Stock

Showing 1 to 50 of 500 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

26.89% Gain from 52W Low

High volume today

Insider Trading disclosures for National Health Investors, Inc.

The latest disclosure was made by Candice W. Todd in National Health Investors, Inc. where a trade of 10,000 Stock Option (Right to Buy) 2025 done was reported to US exchanges on March 3, 2025.

Screeners based on Insider Trading and SAST parameters